Emerging aerosol drug delivery strategies: From bench to clinic

Advanced Drug Delivery Reviews

Volumn 75, Issue , 2014, Pages 141-148

  Rubin, Bruce K ^a   Williams, Ronald W ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aerosol therapy; Engineered particle; Nebulizer; Pressurized metered dose inhaler; Vibrating mesh nebulizer

Indexed keywords

AEROSOLS; DISEASE CONTROL; DRUG INTERACTIONS; TARGETED DRUG DELIVERY; VENTILATION;

AEROSOL DELIVERY; AEROSOL DRUG DELIVERY; MECHANICAL VENTILATION; NEBULIZER; PATIENT COMFORT; PRESSURIZED-METERED DOSE INHALERS; PULMONARY HYPERTENSION; SIDE EFFECT;

CONTROLLED DRUG DELIVERY;

AEROSOL DRUG DELIVERY SYSTEM; ARTIFICIAL VENTILATION; CLINICAL PRACTICE; DIABETES MELLITUS; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; DRY POWDER; FLOW KINETICS; GENE THERAPY; HUMAN; METERED DOSE INHALER; NASAL CANNULA; NEBULIZER; NEOPLASM; NONHUMAN; PATIENT COMFORT; PATIENT SAFETY; QUALITY CONTROL; REVIEW; RISK BENEFIT ANALYSIS; SUSTAINED DRUG RELEASE; VACCINATION; ADMINISTRATION AND DOSAGE; AEROSOL; ANIMAL; INHALATIONAL DRUG ADMINISTRATION;

AEROSOL;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NEBULIZERS AND VAPORIZERS;

EID: 84908258725     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.06.008     Document Type: Review

References (100)

1. Shehata M.A. History of inhalation therapy. Internet J. Health 2009, 9:1-10.
2. Sanders M. Inhalation therapy: an historical review. Prim. Care Respir. J. 2007, 16:71-81.
3. Andrade F., Rafael D., Videira M., Ferreira D., Sosnik A., Sarmento B. Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Adv. Drug Deliv. Rev. 2013, 65:1816-1827.
4. Dessanges J.F. A history of nebulization. J. Aerosol Med. 2001, 14:65-71.
5. Freedman T. Medihaler therapy for bronchial asthma; a new type of aerosol therapy. Postgrad. Med. 1956, 20:667-673.
6. Frijlink H.W., De Boer A.H. Dry powder inhalers for pulmonary drug delivery. Expert Opin. Drug Deliv. 2004, 1:67-86.
7. Rubin B.K., Fink J.B. The delivery of inhaled medication to the young child. Pediatr. Clin. N. Am. 2003, 50:717-731.
8. Rubin B.K. Air and soul: the science and application of aerosol therapy. Respir. Care 2010, 55:911-921.
9. Iles R., Lister P., Edmunds A.T. Crying significantly reduces absorption of aerosolised drug in infants. Arch. Dis. Child. 1999, 81:163-165.
10. Rubin B.K. Bye-bye, blow-by. Respir. Care 2007, 52:981.
11. Laube B.L., Janssens H.M., de Jongh F.H.C., Devadason S.G., Dhand R., Diot P., et al. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 2011, 37:1308-1331.
12. Voeurng V., Andrieu V., Bun H., Reynier J.-P., Dubus J.C. A new small volume holding chamber for asthmatic children: comparison with Babyhaler spacer. Pediatr. Allergy Immunol. 2006, 17:629-634.
13. Blake K., Mehta R., Spencer T., Kunka R.L., Hendeles L. Bioavailability of inhaled fluticasone propionate via chambers/masks in young children. Eur. Respir. J. 2012, 39:97-103.
14. Amirav I., Luder A.S., Halamish A., Raviv D., Kimmel R., Waisman D., et al. Design of aerosol face masks for children using computerized 3D face analysis. J. Aerosol Med. Pulm. Drug Deliv. 2013, 26:1-7.
15. Amirav I., Luder A., Chleechel A., Newhouse M.T., Gorenberg M. Lung aerosol deposition in suckling infants. Arch. Dis. Child. 2012, 97:497-501.
16. Jan Mazela R.A.P. Aerosol delivery to ventilated newborn infants: historical challenges and new directions. Eur. J. Pediatr. 2011, 170:433.
17. Luyt C.-E., Bréchot N., Combes A., Trouillet J.-L., Chastre J. Delivering antibiotics to the lungs of patients with ventilator-associated pneumonia: an update. Expert. Rev. Anti Infect. Ther. 2013, 11:511-521.
18. Fink J., Ari A. Aerosol delivery to intubated patients. Expert Opin. Drug Deliv. 2013, 10:1077-1093.
19. Geller D.E. The science of aerosol delivery in cystic fibrosis. Pediatr. Pulmonol. 2008, 43:S5-S17.
20. Rubin B.K. Pediatric aerosol therapy: new devices and dew drugs. Respir. Care 2011, 56:1411-1423.
21. Ari A., Atalay O.T., Harwood R., Sheard M.M., Aljamhan E.A., Fink J.B. Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation. Respir. Care 2010, 55:845-851.
22. Longest P.W., Azimi M., Hindle M. Optimal delivery of aerosols to infants during mechanical ventilation. J. Aerosol Med. Pulm. Drug Deliv. 2013, 27:1-15.
23. Ari A., Areabi H., Fink J.B. Evaluation of aerosol generator devices at 3 locations in humidified and non-humidified circuits during adult mechanical ventilation. Respir. Care 2010, 55:837-844.
24. Daniels T., Mills N., Whitaker P. Nebuliser systems for drug delivery in cystic fibrosis. Cochrane Database Syst. Rev. 2013, 4:CD007639.
25. Brand P., Schulte M., Wencker M., Herpich C.H., Klein G., Hanna K., et al. Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency. Eur. Respir. J. 2009, 34:354-360.
26. McNamara P.S., McCormack P., McDonald A.J., Heaf L., Southern K.W. Open adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with cystic fibrosis. J. Cyst. Fibros. 2009, 8:258-263.
27. Bhashyam A.R., Wolf M.T., Marcinkowski A.L., Saville A., Thomas K., Carcillo J.A., et al. Aerosol delivery through nasal cannulas: an in vitro study. J. Aerosol Med. Pulm. Drug Deliv. 2008, 21:181-188.
28. Longest P.W., Walenga R.L., Son Y.J., Hindle M. High-efficiency generation and delivery of aerosols through nasal cannula during noninvasive ventilation. J. Aerosol Med. Pulm. Drug Deliv. 2013, 26:266-279.
29. Ari A., Harwood R., Sheard M., Dailey P., Fink J.B. In vitro comparison of heliox and oxygen in aerosol delivery using pediatric high flow nasal cannula. Pediatr. Pulmonol. 2011, 46:795-801.
30. Walter J. Size distribution characteristics of aerosols. Aerosol Measurement: Principles, Techniques, and Applications 2005, 41-54. Wiley-Interscience. 2nd ed.
31. Gonda I. Targeting by deposition. Pharmaceutical Inhalation Aerosol Technology 2003, 65-88. Informa Healthcare. 2nd ed. A.J. Hickey (Ed.).
32. Clark A.R., Chambers C.B., Muir D., Newhouse M.T., Paboojian S., Schuler C. The effect of biphasic inhalation profiles on the deposition and clearance of coarse (6.5microm) bolus aerosols. J. Aerosol Med. 2007, 20:75-82.
33. Edwards D.A., Ben-Jebria A., Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J. Appl. Physiol. 1998, 85:379-385.
34. Bharti N., Kumar S.L.H., Budhiraja A. Pulmonary drug delivery as a vital route for delivering nanoparticles. World J. Pharm. Pharm. Sci. 2013, 2:4037-4060.
35. Yang Y., Bajaj N., Xu P., Ohn K., Tsifansky M.D., Yeo Y. Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials 2009, 30:1947-1953.
36. Edwards D.A., Hanes J., Caponetti G., Hrkach J., Ben-Jebria A., Eskew M.L., et al. Large porous particles for pulmonary drug delivery. Science 1997, 276:1868-1871.
37. Da Silva A.L., Santos R.S., Xisto D.G., Alonso S.D.V., Morales M.M., Rocco P.R.M. Nanoparticle-based therapy for respiratory diseases. An. Acad. Bras. Cienc. 2013, 85:137-146.
38. Geller D.E., Weers J., Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology. J. Aerosol Med. Pulm. Drug Deliv. 2011, 24:175-182.
39. D'Addio S.M., Chan J.G.Y., Kwok P.C.L., Benson B.R., Prud'homme R.K., Chan H.K. Aerosol delivery of nanoparticles in uniform mannitol carriers formulated by ultrasonic spray freeze drying. Pharm. Res. 2013, 30:2891-2901.
40. Pham D.-D., Fattal E., Ghermani N., Guiblin N., Tsapis N. Formulation of pyrazinamide-loaded large porous particles for the pulmonary route: avoiding crystal growth using excipients. Int. J. Pharm. 2013, 454:668-677.
41. Willis L., Hayes D., Mansour H.M. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung 2012, 190:251-262.
42. Meenach S.A., Anderson K.W., Zach Hilt J., McGarry R.C., Mansour H.M. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. Eur. J. Pharm. Sci. 2013, 49:699-711.
43. Smutney C.C., Grant M., Kinsey P.S. Device factors affecting pulmonary delivery of dry powders. Ther. Deliv. 2013, 4:939-949.
44. Konduri K.S., Nandedkar S., Düzgünes N., Suzara V., Artwohl J., Bunte R., et al. Efficacy of liposomal budesonide in experimental asthma. J. Allergy Clin. Immunol. 2003, 111:321-327.
45. Frankenberger M., Haussinger K., Zieglerheitbrock L. Liposomal methylprednisolone differentially regulates the expression of TNF and IL-10 in human alveolar macrophages. Int. Immunopharmacol. 2005, 5:289-299.
46. Chen X., Huang W., Wong B.C., Yin L., Wong Y.F., Xu M., et al. Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. Int. J. Nanomedicine 2012, 7:1139-1148.
47. Serisier D.J., Bilton D., De Soyza A., Thompson P.J., Kolbe J., Greville H.W., et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013, 68:812-817.
48. Lee J.-H., Cheng K.T., Malinin V., Li Z., Yao Z., Lee S.-J., et al. (99m)Tc-labeled therapeutic inhaled amikacin loaded liposomes. J. Liposome Res. 2013, 23:336-342.
49. Wallace S.J., Nation R.L., Li J., Boyd B.J. Physicochemical aspects of the coformulation of colistin and azithromycin using liposomes for combination antibiotic therapies. J. Pharm. Sci. 2013, 102:1578-1587.
50. Leleu C., Menotti J., Meneceur P., Choukri F., Sulahian A., Garin Y.J.-F., et al. Efficacy of liposomal amphotericin B for prophylaxis of acute or reactivation models of invasive pulmonary aspergillosis. Mycoses 2013, 56:241-249.
51. Vyas S.P., Kannan M.E., Jain S., Mishra V., Singh P. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int. J. Pharm. 2004, 269:37-49.
52. Chougule M., Padhi B., Misra A. Development of spray dried liposomal dry powder inhaler of Dapsone. AAPS PharmSciTech 2008, 9:47-53.
53. Ivanova V., Garbuzenko O.B., Reuhl K.R., Reimer D.C., Pozharov V.P., Minko T. Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2. Eur. J. Pharm. Biopharm. 2013, 84:335-344.
54. Parmar J.J., Singh D.J., Lohade A.A., Hegde D.D., Soni P.S., Samad A., et al. Inhalational system for Etoposide liposomes: formulation development and in vitro deposition. Indian J. Pharm. Sci. 2011, 73:656-662.
55. Chougule M., Padhi B., Misra A. Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics. Int. J. Nanomedicine 2007, 2:675-688.
56. Yin Y., Wu X., Yang Z., Zhao J., Wang X., Zhang Q., et al. The potential efficacy of R8-modified paclitaxel-loaded liposomes on pulmonary arterial hypertension. Pharm. Res. 2013, 30:2050-2062.
57. Newhouse M.T., Hirst P.H., Duddu S.P., Walter Y.H., Tarara T.E., Clark A.R., et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 2003, 124:360-366.
58. Lai S.K., Wang Y.-Y., Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 2009, 61:158-171.
59. Savla R., Minko T. Nanotechnology approaches for inhalation treatment of fibrosis. J. Drug Target. 2013, 21:914-925.
60. Suk J.S., Lai S.K., Wang Y.-Y., Ensign L.M., Zeitlin P.L., Boyle M.P., et al. The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials 2009, 30:2591-2597.
61. Suk J.S., Lai S.K., Boylan N.J., Dawson M.R., Boyle M.P., Hanes J. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. Nanomedicine (Lond.) 2011, 6:365-375.
62. Tewes F., Paluch K.J., Tajber L., Gulati K., Kalantri D., Ehrhardt C., et al. Steroid/mucokinetic hybrid nanoporous microparticles for pulmonary drug delivery. Eur. J. Pharm. Biopharm. 2013, 85:604-613.
63. Nasr M., Nawaz S., Elhissi A. Amphotericin B lipid nanoemulsion aerosols for targeting peripheral respiratory airways via nebulization. Int. J. Pharm. 2012, 436:611-616.
64. Vyas S.P., Khatri K. Liposome-based drug delivery to alveolar macrophages. Expert Opin. Drug Deliv. 2007, 4:95-99.
65. Chono S., Tanino T., Seki T., Morimoto K. Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J. Control. Release 2008, 127:50-58.
66. Dhanda D.S., Tyagi P., Mirvish S.S., Kompella U.B. Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose. J. Control. Release 2013, 168:239-250.
67. Kim H.K., Chung H.J., Park T.G. Biodegradable polymeric microspheres with "open/closed" pores for sustained release of human growth hormone. J. Control. Release 2006, 112:167-174.
68. Kwon M.J., Bae J.H., Kim J.J., Na K., Lee E.S. Long acting porous microparticle for pulmonary protein delivery. Int. J. Pharm. 2007, 333:5-9.
69. Ryan G.M., Kaminskas L.M., Kelly B.D., Owen D.J., McIntosh M.P., Porter C.J.H. Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent. Mol. Pharm. 2013, 10:2986-2995.
70. Beck-Broichsitter M., Rieger M., Reul R., Gessler T., Seeger W., Schmehl T. Correlation of drug release with pulmonary drug absorption profiles for nebulizable liposomal formulations. Eur. J. Pharm. Biopharm. 2013, 84:106-114.
71. Cutts F.T., Clements C.J., Bennett J.V. Alternative routes of measles immunization: a review. Biologicals 1997, 25:323-338.
72. Sabin A.B., Flores Arechiga A., Fernández de Castro J., Sever J.L., Madden D.L., Shekarchi I., et al. Successful immunization of children with and without maternal antibody by aerosolized measles vaccine. I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines. JAMA 1983, 249:2651-2662.
73. Sabin A.B., Flores Arechiga A., Fernández de Castro J., Albrecht P., Sever J.L., Shekarchi I. Successful immunization of infants with and without maternal antibody by aerosolized measles vaccine. II. Vaccine comparisons and evidence for multiple antibody response. JAMA 1984, 251:2363-2371.
74. LiCalsi C., Christensen T., Bennett J.V., Phillips E., Witham C. Dry powder inhalation as a potential delivery method for vaccines. Vaccine 1999, 17:1796-1803.
75. Bennett J.V., Fernandez De Castro J., Valdespino-Gomez J.L., Garcia Garcia M.L., Islas-Romero R., Echaniz-Aviles G., et al. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren. Bull. World Health Organ. 2002, 80:806-812.
76. LiCalsi C., Maniaci M.J., Christensen T., Phillips E., Ward G.H., Witham C. A powder formulation of measles vaccine for aerosol delivery. Vaccine 2001, 19:2629-2636.
77. Garcia-Contreras L., Wong Y.-L., Muttil P., Padilla D., Sadoff J., Derousse J., et al. Immunization by a bacterial aerosol. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:4656-4660.
78. Tyne A.S., Chan J.G.Y., Shanahan E.R., Atmosukarto I., Chan H.K., Britton W.J., et al. TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines. Vaccine 2013, 31:4322-4329.
79. Murugappan S., Patil H.P., Kanojia G., Ter Veer W., Meijerhof T., Frijlink H.W., et al. Physical and immunogenic stability of spray freeze-dried influenza vaccine powder for pulmonary delivery: comparison of inulin, dextran, or a mixture of dextran and trehalose as protectants. Eur. J. Pharm. Biopharm. 2013, 85:716-725.
80. Kunda N.K., Somavarapu S., Gordon S.B., Hutcheon G.A., Saleem I.Y. Nanocarriers targeting dendritic cells for pulmonary vaccine delivery. Pharm. Res. 2013, 30:325-341.
81. Gänsslen M. Über Inhalation von Insulin. Klin. Wochenschr. 1925, 4:71.
82. Sakagami M. Systemic delivery of biotherapeutics through the lung: opportunities and challenges for improved lung absorption. Ther. Deliv. 2013, 4:1511-1525.
83. Angelo R., Rousseau K., Grant M., Leone-Bay A., Richardson P. Technosphere insulin: defining the role of Technosphere particles at the cellular level. J. Diabetes Sci. Technol. 2009, 3:545-554.
84. Boss A.H., Petrucci R., Lorber D. Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin. J. Diabetes Sci. Technol. 2012, 6:773-779.
85. Depreter F., Burniat A., Blocklet D., Lacroix S., Cnop M., Fery F., et al. Comparative pharmacoscintigraphic and pharmacokinetic evaluation of two new formulations of inhaled insulin in type 1 diabetic patients. Eur. J. Pharm. Biopharm. 2012, 80:4-13.
86. Coates A.L. Guiding aerosol deposition in the lung. N. Engl. J. Med. 2008, 358:304-305.
87. Rudolph C., Gleich B., Flemmer A.W. Magnetic aerosol targeting of nanoparticles to cancer: nanomagnetosols. Methods Mol. Biol. 2010, 624:267-280.
88. Hasenpusch G., Geiger J., Wagner K., Mykhaylyk O., Wiekhorst F., Trahms L., et al. Magnetized aerosols comprising superparamagnetic iron oxide nanoparticles improve targeted drug and gene delivery to the lung. Pharm. Res. 2012, 29:1308-1318.
89. Tewes C.Ehrhardt, Healy A.M. Superparamagnetic iron oxide nanoparticles (SPIONs)-loaded Trojan microparticles for targeted aerosol delivery to the lung. Eur. J. Pharm. Biopharm. 2014, 86:98-104.
90. Gautier J., Munnier E., Paillard A., Hervé K., Douziech-Eyrolles L., Soucé M., et al. A pharmaceutical study of doxorubicin-loaded PEGylated nanoparticles for magnetic drug targeting. Int. J. Pharm. 2012, 423:16-25.
91. Liu D., Wu W., Chen X., Wen S., Zhang X., Ding Q., et al. Conjugation of paclitaxel to iron oxide nanoparticles for tumor imaging and therapy. Nanoscale 2012, 4:2306-2310.
92. Upadhyay D., Scalia S., Vogel R., Wheate N., Salama R.O., Young P.M., et al. Magnetised thermo responsive lipid vehicles for targeted and controlled lung drug delivery. Pharm. Res. 2012, 29:2456-2467.
93. Zulauf G.D., Trembly B.S., Giustini A.J., Flint B.R., Strawbridge R.R., Hoopes P.J. Targeting of systemically-delivered magnetic nanoparticle hyperthermia using a noninvasive, static, external magnetic field. Proc SPIE 2013, 1-13.
94. Giustini A.J., Petryk A.A., Cassim S.M., Tate J.A., Baker I., Hoopes P.J. Magnetic nanoparticle hyperthermia in cancer treatment. Nano Life 2010, 1:1-23.
95. Laube B.L. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir. Care 2005, 50:1161-1176.
96. Gautam A., Waldrep J.C., Densmore C.L. Aerosol gene therapy. Mol. Biotechnol. 2003, 23:51-60.
97. Stribling R., Brunette E., Liggitt D., Gaensler K., Debs R. Aerosol gene delivery in vivo. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:11277-11281.
98. Bellon G., Michel-Calemard L., Thouvenot D., Jagneaux V., Poitevin F., Malcus C., et al. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum. Gene Ther. 1997, 8:15-25.
99. Ramsey J.M., Hibbitts A., Barlow J., Kelly C., Sivadas N., Cryan S.-A. "Smart" non-viral delivery systems for targeted delivery of RNAi to the lungs. Ther. Deliv. 2013, 4:59-76.
100. Collet G., Grillon C., Nadim M., Kieda C. Trojan horse at cellular level for tumor gene therapies. Gene 2013, 525:208-216.